Holen Sie sich die Stockscreener-App
25.65
2.07%
0.52
Handel nachbörslich:
25.60
-0.05
-0.19%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$25.13
Offen:
$25.18
24-Stunden-Volumen:
40.89M
Relative Volume:
1.18
Marktkapitalisierung:
$145.36B
Einnahmen:
$59.37B
Nettoeinkommen (Verlust:
$4.25B
KGV:
14.02
EPS:
1.83
Netto-Cashflow:
$8.23B
1W Leistung:
+3.43%
1M Leistung:
-11.06%
6M Leistung:
-13.34%
1J Leistung:
-15.40%
1-Tages-Spanne:
$25.10
$25.75
1-Wochen-Bereich:
$24.61
$25.75
52-Wochen-Spanne:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| PFE | 25.65 | 145.36B | 59.37B | 4.25B | 8.23B | 1.83 |
| LLY | 748.01 | 710.91B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 105.06 | 466.80B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 155.17 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 176.95 | 312.70B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 99.18 | 250.89B | 63.17B | 12.15B | 14.84B | 1.80 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Laurel Lee from Florida's 15th district makes notable trades in Apple, GE Vernova, and Pfizer - Investing.com
Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby - Seeking Alpha
3 Dividend Stocks That Are Screaming Buys in November - The Motley Fool
Meridian Wealth Management LLC Takes Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively - Yahoo Finance
CFS Investment Advisory Services LLC Trims Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Women Health Market Growing Popularity and Emerging Trends in the Industry Analysis by Key Players-Pfizer I... - WhaTech
Las Vegas woman sues Pfizer after tumors possibly linked to birth control shot - AOL
BridgeBio Gets US Approval for Heart Drug to Compete with Pfizer - BNN Bloomberg
Zai Lab, Pfizer team up to widen China access to antibacterial Xacduro - BioWorld Online
Pfizer (NYSE:PFE) Shares Up 1.8%Still a Buy? - MarketBeat
Investors Purchase Large Volume of Call Options on Pfizer (NYSE:PFE) - MarketBeat
Pfizer Stock Drops 10% In November On News Of Kennedy's HHS NominationPfizer (NYSE:PFE) - Benzinga
Pfizer to help commercialize Xacduro in China - The Pharma Letter
Depo Provera Lawsuit - Lawsuit Information Center Blog
Zai Lab partners with Pfizer to commercialise Xacduro in China - World Pharmaceutical Frontiers
Landscape Capital Management L.L.C. Invests $1.32 Million in Pfizer Inc. (NYSE:PFE) - MarketBeat
Zai Lab and Pfizer to commercialise XACDURO in China - Pharmaceutical Technology
Pfizer’s New Strategy Head Grapples With Some Blockbuster Problems - Citeline News & Insights
Morocco fines Viatris 7.58 million dirhams over Mylan-Pfizer merger - Yabiladi in English
Kidney Cancer Drugs Market Huge Growth in Future Scope 2024-2031 - openPR
Monoclonal Antibody Therapeutics Market Is Booming Worldwide - openPR
Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks (NYSE:PFE) - Seeking Alpha
Pfizer (NYSE:PFE) Trading Down 0.2%Should You Sell? - MarketBeat
Amgen and Pfizer appoint new Science executives - Marketscreener.com
Integrated Investment Consultants LLC Raises Stake in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
Pfizer Names New Head Of Research And Development - Baystreet.ca
The Zacks Analyst Blog Highlights Adobe, Pfizer, Dollar General, Snap and Ryanair - Zacks Investment Research
Mizuho Securities USA LLC Sells 69,459 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Is Pfizer Stock A Sell With Vaccine Skeptic Robert F. Kennedy Jr. Tapped To Lead HHS? - Yahoo! Voices
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU - Yahoo Finance
Pfizer Inc. (NYSE:PFE) Shares Acquired by America First Investment Advisors LLC - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 4,546,809 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Intech Investment Management LLC - MarketBeat
The Escalator: Pfizer, Eli Lilly, CVS Health and more - MM+M Online
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam) - BioSpace
Ontario Teachers Pension Plan Board Has $1.12 Million Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Appoints Cancer Research Head Chris Boshoff as New R&D Chief - GuruFocus.com
Pfizer elevates Chris Boshoff to top R&D role - pharmaphorum
Mitochondrial-Based Therapeutics Market Key Players Analysis - openPR
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO - Business Wire
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia - Pharmaceutical Technology
PFIZER INC. (PFE) - MSN
Pfizer, Flynn Still Face Fines Over Epilepsy Drug Sale To NHS - Law360
Meta, Pfizer on DOL List of Upcoming Contractor Anti-Bias Audits - Bloomberg Law
Health Care Climbs as Obesity-Drug Makers ReboundHealth Care Roundup - Marketscreener.com
How Pfizer is trying to make U.S. healthcare easier to navigate - Fast Company
Pfizer Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Pfizer Picks Boshoff To Head R&D, A Smooth Transition In An Uncertain Time - Citeline News & Insights
Pfizer (NYSE:PFE) Stock Price Down 0.6%Should You Sell? - MarketBeat
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.60%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):